论文部分内容阅读
目的:观察蒙药复方通拉嘎-5联合泮托拉唑治疗慢性糜烂性胃炎的临床疗效。方法:将慢性糜烂性胃炎患者36例,随机分为两组,治疗组18例,给予蒙药通拉嘎-5联合泮托拉唑治疗;对照组18例,只给予泮托拉唑治疗;其中幽门螺杆菌(HP)阳性者给予HP根除标准三联治疗。治疗4周为1疗程,治疗结束后,比较两组的临床疗效和不良反应情况。结果:两组在治疗后比较,各项临床症状的改善和疼痛消失差异具有统计学意义(P<0.05);慢性糜烂性胃炎总有效率治疗组为88.88%,对照组为72.21%,两组比较差异有统计学意义(P<0.05)。用药期间,两组均未出现明显不良反应。结论:蒙药复方通拉嘎-5联合泮托拉唑治疗慢性糜烂性胃炎疗效显著,症状改善快,可在临床推广应用。
Objective: To observe the clinical efficacy of Mongolian compound Tonglaga-5 combined with Pantoprazole in the treatment of chronic erosive gastritis. Methods: Thirty-six patients with chronic erosive gastritis were randomly divided into two groups. The treatment group was treated with Tonglaga-5 plus pantoprazole Mongolian drug. In the control group, 18 cases were treated with pantoprazole only. Helicobacter pylori (HP) positive persons are given HP eradication standard triple therapy. Treatment for 4 weeks for a course of treatment, after treatment, the two groups were compared the clinical efficacy and adverse reactions. Results: After treatment, the improvement of clinical symptoms and the disappearance of pain were statistically significant (P <0.05). The total effective rate of chronic erosive gastritis was 88.88% in the treatment group and 72.21% in the control group The difference was statistically significant (P <0.05). During the medication, no obvious adverse reactions occurred in both groups. CONCLUSION: Mongolian compound Tonglaga-5 combined with pantoprazole has significant curative effect on chronic erosive gastritis and rapid improvement of symptoms. It can be widely used clinically.